PubMed

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators.

Cardiovasc Diabetol. 2005 Aug 22;4:13.PMID: 16111499 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420. PMID: 16310551 [PubMed - indexed for MEDLINE]Related articles

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.PMID: 16259526 [PubMed - indexed for MEDLINE]Related articles

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.

Diabetes Care. 2009 Mar;32(3):493-8. Epub 2008 Nov 4.PMID: 18984774 [PubMed - indexed for MEDLINE]Related articlesFree article

Increasing high-density lipoprotein cholesterol: an update on fenofibrate.

Després JP.

Am J Cardiol. 2001 Dec 20;88(12A):30N-36N. Review.PMID: 11788128 [PubMed - indexed for MEDLINE]Related articles

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.

Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.

Clin Ther. 2004 Oct;26(10):1599-607.PMID: 15598476 [PubMed - indexed for MEDLINE]Related articles

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, Taskinen MR.

Diabetologia. 2007 Oct;50(10):2067-75. Epub 2007 Jul 26. Erratum in: Diabetologia. 2007 Dec;50(12):2611-3. PMID: 17653691 [PubMed - indexed for MEDLINE]Related articles

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.

[No authors listed]

Eur Heart J. 1999 May;20(10):725-41.PMID: 10329064 [PubMed - indexed for MEDLINE]Related articlesFree article

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.PMID: 17599422 [PubMed - indexed for MEDLINE]Related articles

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators.

Lancet. 2009 May 23;373(9677):1780-8.PMID: 19465233 [PubMed - indexed for MEDLINE]Related articlesFree article

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.

Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.

Endocr Pract. 2002 Mar-Apr;8(2):96-101.PMID: 11942772 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

Hay JW, Sterling KL.

Pharmacoeconomics. 2005;23(2):133-41.PMID: 15748088 [PubMed - indexed for MEDLINE]Related articles

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Keating GM, Croom KF.

Drugs. 2007;67(1):121-53. Review.PMID: 17209672 [PubMed - indexed for MEDLINE]Related articles

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Keating GM, Ormrod D.

Drugs. 2002;62(13):1909-44. Review.PMID: 12215067 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.

Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A; Study Investigators.

Am J Cardiovasc Drugs. 2009;9(2):91-101. doi: 10.2165/00129784-200909020-00003.PMID: 19331437 [PubMed - indexed for MEDLINE]Related articles

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

N Engl J Med. 1999 Aug 5;341(6):410-8.PMID: 10438259 [PubMed - indexed for MEDLINE]Related articlesFree article

How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.

Steiner G.

Cardiovasc Drugs Ther. 2009 Oct;23(5):403-8. Review.PMID: 19757004 [PubMed - indexed for MEDLINE]Related articles

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group.

Lancet. 2003 Jun 14;361(9374):2005-16.PMID: 12814710 [PubMed - indexed for MEDLINE]Related articles

Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.

Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M.

Diabetes. 1997 Aug;46(8):1354-9.PMID: 9231662 [PubMed - indexed for MEDLINE]Related articles

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.

Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E.

Circulation. 2002 Mar 26;105(12):1424-8.PMID: 11914249 [PubMed - indexed for MEDLINE]Related articlesFree article